Regenerative Medicine Firm Cesca Therapeutics Eyeing Major Device Players
This article was originally published in The Gray Sheet
Executive Summary
The new company, forming from the merger of ThermoGenesis and TotipotentRx, aims to use its cell processing systems and cell formulations to recast the way physicians treat various cardiovascular and orthopedic problems. It is in discussions with device firms about potential partnerships.
You may also be interested in...
FDA Finds Gaps In Cesca's Stem Cell Trial Plan For Critical Limb Ischemia
The agency noted deficiencies in Cesca Therapeutcs' investigational device exemption submission for the CLIRST III pivotal study of its SurgWerks stem cell therapy system in critical limb ischemia. But the company says the overall message for the 224-patient study is positive.
News Briefs: User Fee Bill, Sunshine Mobile Apps, More
The House introduced a bill that would exempt device and drug user fees from sequestration cuts. CMS releases two mobile apps to help track payments required under the Sunshine law. More news.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.